

World Journal of *Clinical Cases*

World J Clin Cases 2022 December 6; 10(34): 12462-12803



Contents

Thrice Monthly Volume 10 Number 34 December 6, 2022

FIELD OF VISION

- 12462** Problematics of neurosurgical service during the COVID-19 pandemic in Slovenia
Munda M, Bosnjak R, Velnar T

MINIREVIEWS

- 12470** Circulating angiotensin converting enzyme 2 and COVID-19
Leowattana W, Leowattana T, Leowattana P
- 12484** Evaluation of gut dysbiosis using serum and fecal bile acid profiles
Monma T, Iwamoto J, Ueda H, Tamamushi M, Kakizaki F, Konishi N, Yara S, Miyazaki T, Hirayama T, Ikegami T, Honda A
- 12494** Pediatric kidney transplantation during the COVID-19 pandemic
Tamura H

ORIGINAL ARTICLE

Clinical and Translational Research

- 12500** *Coptis*, *Pinellia*, and *Scutellaria* as a promising new drug combination for treatment of *Helicobacter pylori* infection
Yu Z, Sheng WD, Yin X, Bin Y

Case Control Study

- 12515** Effects of illness perception on negative emotions and fatigue in chronic rheumatic diseases: Rumination as a possible mediator
Lu Y, Jin X, Feng LW, Tang C, Neo M, Ho RC

Retrospective Study

- 12532** Significance of incidental focal fluorine-18 fluorodeoxyglucose uptake in colon/rectum, thyroid, and prostate: With a brief literature review
Lee H, Hwang KH
- 12543** Follow-up study on ThinPrep cytology test-positive patients in tropical regions
Chen YC, Liang CN, Wang XF, Wang MF, Huang XN, Hu JD
- 12551** Effect of teach-back health education combined with structured psychological nursing on adverse emotion and patient cooperation during ^{99m}Tc -3PRGD2.SPECT/CT
Gong WN, Zhang YH, Niu J, Li XB
- 12559** Nosocomial infection and spread of SARS-CoV-2 infection among hospital staff, patients and caregivers
Cheng CC, Fann LY, Chou YC, Liu CC, Hu HY, Chu D

Observational Study

- 12566** Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, Al Qamish J

- 12578** Influence of group B *streptococcus* and vaginal cleanliness on the vaginal microbiome of pregnant women
Liao Q, Zhang XF, Mi X, Jin F, Sun HM, Wang QX

Randomized Controlled Trial

- 12587** Clinical study on tri-tongue acupuncture combined with low-frequency electrical stimulation for treating post-stroke dysarthria
Man B, Li WW, Xu JF, Wang Q

META-ANALYSIS

- 12594** Three-dimensional time-of-flight magnetic resonance angiography combined with high resolution T2-weighted imaging in preoperative evaluation of microvascular decompression
Liang C, Yang L, Zhang BB, Guo SW, Li RC

CASE REPORT

- 12605** Acute cytomegalovirus hepatitis in an immunocompetent patient: A case report
Wang JP, Lin BZ, Lin CL, Chen KY, Lin TJ
- 12610** Long-term results of extended Boari flap technique for management of complete ureteral avulsion: A case report
Zhong MZ, Huang WN, Huang GX, Zhang EP, Gan L
- 12617** Amyloid β -related angiitis of the central nervous system occurring after COVID-19 vaccination: A case report
Kizawa M, Iwasaki Y
- 12623** Pseudoileus caused by primary visceral myopathy in a Han Chinese patient with a rare *MYH11* mutation: A case report
Li N, Song YM, Zhang XD, Zhao XS, He XY, Yu LF, Zou DW
- 12631** Emergent use of tube tip in pharynx technique in "cannot intubate cannot oxygenate" situation: A case report
Lin TC, Lai YW, Wu SH
- 12637** Inflammatory myofibroblastic tumor of the central nervous system: A case report
Su ZJ, Guo ZS, Wan HT, Hong XY
- 12648** Atypical aggressive vertebral hemangioma of the sacrum with postoperative recurrence: A case report
Wang GX, Chen YQ, Wang Y, Gao CP
- 12654** Closed reduction of hip dislocation associated with ipsilateral lower extremity fractures: A case report and review of the literature
Xu Y, Lv M, Yu SQ, Liu GP

- 12665** Repair of a large patellar cartilage defect using human umbilical cord blood-derived mesenchymal stem cells: A case report
Song JS, Hong KT, Song KJ, Kim SJ
- 12671** Abdominal bronchogenic cyst: A rare case report
Li C, Zhang XW, Zhao CA, Liu M
- 12678** Malignant fibrous histiocytoma of the axilla with breast cancer: A case report
Gao N, Yang AQ, Xu HR, Li L
- 12684** Rapid hemostasis of the residual inguinal access sites during endovascular procedures: A case report
Kim H, Lee K, Cho S, Joh JH
- 12690** Formation of granulation tissue on bilateral vocal cords after double-lumen endotracheal intubation: A case report
Xiong XJ, Wang L, Li T
- 12696** Giant cellular leiomyoma in the broad ligament of the uterus: A case report
Yan J, Li Y, Long XY, Li DC, Li SJ
- 12703** Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
Li X, Pan XH, Fang Q, Liang Y
- 12711** Ureteral- artificial iliac artery fistula: A case report
Feng T, Zhao X, Zhu L, Chen W, Gao YL, Wei JL
- 12717** How to manage isolated tension non-surgical pneumoperitoneum during bronchoscopy? A case report
Baima YJ, Shi DD, Shi XY, Yang L, Zhang YT, Xiao BS, Wang HY, He HY
- 12726** Amiodarone-induced muscle tremor in an elderly patient: A case report
Zhu XY, Tang XH, Yu H
- 12734** Surgical treatment of Pitt-Hopkins syndrome associated with strabismus and early-onset myopia: Two case reports
Huang Y, Di Y, Zhang XX, Li XY, Fang WY, Qiao T
- 12742** Massive low-grade myxoid liposarcoma of the floor of the mouth: A case report and review of literature
Kugimoto T, Yamagata Y, Ohsako T, Hirai H, Nishii N, Kayamori K, Ikeda T, Harada H
- 12750** Gingival enlargement induced by cyclosporine in Medullary aplasia: A case report
Victory Rodríguez G, Ruiz Gutiérrez ADC, Gómez Sandoval JR, Lomeli Martínez SM
- 12761** Compound heterozygous mutations in PMFBP1 cause acephalic spermatozoa syndrome: A case report
Deng TQ, Xie YL, Pu JB, Xuan J, Li XM
- 12768** Colonic tubular duplication combined with congenital megacolon: A case report
Zhang ZM, Kong S, Gao XX, Jia XH, Zheng CN

- 12775** Perforated duodenal ulcer secondary to deferasirox use in a child successfully managed with laparoscopic drainage: A case report
Alshehri A, Alsinan TA
- 12781** Complication after nipple-areolar complex tattooing performed by a non-medical person: A case report
Byeon JY, Kim TH, Choi HJ
- 12787** Interventional urethral balloon dilatation before endoscopic visual internal urethrotomy for post-traumatic bulbous urethral stricture: A case report
Ha JY, Lee MS
- 12793** Regression of gastric endoscopic submucosal dissection induced polypoid nodular scar after *Helicobacter pylori* eradication: A case report
Jin BC, Ahn AR, Kim SH, Seo SY
- 12799** Congenital absence of the right coronary artery: A case report
Zhu XY, Tang XH

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Giuseppe Lanza, MD, MSc, PhD, Associate Professor, Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania 95123, Italy.
glanza@oasi.en.it

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Si Zhao; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

December 6, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Observational Study

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C

Maheeba Abdulla, Aysha Mohamed Al Ghareeb, Hamed Ali Hasan Yusuf Husain, Nafeesa Mohammed, Jehad Al Qamish

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: El Kassas M, Egypt; El-Bendary M, Egypt; Lo SY, Taiwan; Metawea MI, Egypt

Received: July 13, 2022

Peer-review started: July 13, 2022

First decision: August 6, 2022

Revised: September 28, 2022

Accepted: November 8, 2022

Article in press: November 8, 2022

Published online: December 6, 2022



Maheeba Abdulla, Department of Internal Medicine, Salmaniya Medical Complex, Arabian Gulf University, Manama 2904, Bahrain

Aysha Mohamed Al Ghareeb, Hamed Ali Hasan Yusuf Husain, Nafeesa Mohammed, Department of Internal Medicine, Salmaniya Medical Complex, Manama 2904, Bahrain

Jehad Al Qamish, Internal Medicine Department, Ibn AlNafees Hospital, Manama 3302, Bahrain

Corresponding author: Maheeba Abdulla, MD, Doctor, Department of Internal Medicine, Salmaniya Medical Complex, Arabian Gulf University, Rd No. 2904, Manama 2904, Bahrain. amaheeba@gmail.com

Abstract

BACKGROUND

Direct acting antivirals (DAAs) are a very effective treatment for hepatitis C virus (HCV). However, brand DAAs are expensive. The licensing of cheaper generic DAAs may address this issue, but there is a lack of clinical studies comparing the efficacy of generic *vs* brand DAA formulations.

AIM

To compare the efficacy and safety of generic against brand DAAs for chronic hepatitis C treatment in Bahrain.

METHODS

This was a retrospective observational study involving 289 patients with chronic HCV infection during 2016 to 2018. There were 149 patients who were treated with brand DAAs, while 140 patients were treated with generic DAAs. Commonly used DAAs were Ombitasvir/Paritaprevir/Ritonavir \pm Dasabuvir \pm Ribavirin, and Sofosbuvir/Daclatasvir \pm Ribavirin. SVR at 12 wk post treatment was the main outcome variable.

RESULTS

Overall, 87 patients (30.1%) had cirrhosis and 68.2% had genotype 1 HCV infection. At 12 wk post treatment, SVR was achieved by 271 (93.8%) of the patients. In patients who were treated with generic medications, 134 (95.7%) achieved SVR at 12 wk post treatment, compared to 137 (91.9%) among those

treated with brand medications ($P = 0.19$). Having cirrhosis [odds ratio (OR): 9.41, 95% confidence interval (CI): 2.47–35.84] and having HCV genotype 3 (OR: 3.56, 95% CI: 1.03–12.38) were significant independent predictors of not achieving SVR. Alanine transaminase, gamma-glutamyl transpeptidase, and total bilirubin levels decreased significantly following therapy with both generic and brand DAAs.

CONCLUSION

Generic and brand DAAs demonstrate comparable effectiveness in the treatment of chronic hepatitis C patients. Both are safe and equally effective in improving biochemical markers of hepatic inflammation.

Key Words: Hepatitis C virus; Direct acting antivirals; Generic; Brand; Sofosbuvir; Ombitasvir; Ledipasvir; Daclatasvir; Paritaprevir; Ritonavir; Dasabuvir; Ribavirin; Sustained virologic response

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The World Health Organization aims to eliminate hepatitis C virus (HCV) infection by 2030. Its guidelines recommend treatment for all individuals diagnosed with HCV infection for > 12 years. Management of HCV infection in low- and middle-income countries is hampered by high costs of medication. This is the first study to compare efficacy and safety of generic compared to original brand direct acting antivirals (DAAs) for hepatitis C treatment in Bahrain, where the prevalence of HCV infection is estimated to be 1.7% (1.39–2.21%). Overall, our study adds to the literature on the similarity in effectiveness in patients receiving both brand and generic formulations of DAAs for chronic hepatitis C.

Citation: Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, Al Qamish J. Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C. *World J Clin Cases* 2022; 10(34): 12566–12577

URL: <https://www.wjgnet.com/2307-8960/full/v10/i34/12566.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i34.12566>

INTRODUCTION

Over 71 million individuals live with hepatitis C virus (HCV) globally, equivalent to 1% of the world's population[1]. Furthermore, approximately 5 million new cases of HCV were diagnosed in 2015[2]. HCV can present as an acute or a chronic infection. Acute HCV infection does not present with symptoms and up to 30% (15%–45%) of affected persons spontaneously eliminate the virus within 6 mo without medication[3]. However, roughly 70% of HCV infected persons develop chronic infection, and up to 30% of those will develop cirrhosis and hepatocellular carcinoma within 20 years – eventually leading to almost 1 million deaths annually[3,4]. Achieving a sustained virologic response (SVR), where the HCV RNA levels remain undetectably low, has been associated with a reduction in liver-associated complications, improvement in health-related quality of life, and reduction in the need for liver transplantation among individuals with chronic hepatitis C[4–6].

Direct acting antivirals (DAAs) have revolutionized the treatment landscape for patients with chronic hepatitis C because they have been shown to demonstrate high SVR rates[7,8]. In response to this, the World Health Organization (WHO) proposed strategies for the elimination of HCV infection by 2030[9]. Achieving the HCV elimination strategy requires the diagnosis of 90% of those with hepatitis C, followed by treatment of 80% of those diagnosed – this will ultimately lead to an 80% reduction in new HCV infections, and a 65% reduction in HCV-associated mortality[8,9]. Furthermore, the WHO updated its chronic hepatitis C guidelines recommending treatment for all individuals diagnosed with HCV infection who are 12 years of age or older, irrespective of disease stage[9].

The uptake of DAAs in the management of HCV infection in several countries, especially in low- and middle-income countries (LMICs), has been hampered by the high cost of medications[10]. Moreover, the increase in the rate of new HCV infections, the low rate of testing for HCV infection globally, and patent ownership rights and restrictions by brand name companies producing the DAAs, have hampered the production of their generic versions; and low rates of treatment in LMICs (harboring 72% of HCV burden) continue to threaten the attainment of the WHO HCV elimination goal[7]. With the increasing voluntary license permission being granted to companies producing generic DAAs by brand name manufacturers, the use of generic DAAs has substantially improved access to hepatitis C treatment in developing countries[11,12]. However, there are increasing concerns regarding the safety and efficacy of generic DAA formulations. A pharmacokinetic study has revealed similar bioequi-

valence between the generic and brand DAA formulations[13], and several real-world studies of generic DAAs and their systematic review have reported high SVR rates of 92%-98% in HCV infected patients irrespective of their genotype[7,14-15]. Despite these findings, comparative studies assessing the effectiveness and safety of generic *vs* brand DAA formulations for hepatitis C treatment are needed before its adoption, but only a few of these studies, carried out in India and Egypt, have been reported[16-18].

In Bahrain, the prevalence of HCV infection is estimated to be 1.7% (1.39%-2.21%)[2]. The predominant HCV genotype among Bahraini patients is type 1, followed by genotypes 3 and 4, and the lowest frequency is for genotype 2[19,20]. There is a real-world study of DAAs for hepatitis C treatment in Bahrain[21], but no study has compared the effectiveness of generic *vs* brand DAAs for hepatitis C treatment in the country. Therefore, the objective of this study was to compare the efficacy and safety of generic *vs* brand DAAs for chronic hepatitis C treatment in Bahrain.

MATERIALS AND METHODS

Study design

This was a retrospective observational study involving 289 patients with a real time reverse transcriptase-polymerase chain reaction (real-time RT-PCR) diagnosis of chronic HCV infection (*i.e.*, for over 6 mo) who qualified for antiviral treatment. The patients were enrolled from the hepatology clinic of Salmaniya Medical Complex, Bahrain from January 2016 to December 2018. All patients gave written informed consent before participating in the study, and approval for the study was received from the Secondary Health Care Research Sub Committee, Ministry of Health, Kingdom of Bahrain (Reference number 22G45-40-01925).

Study participants

Patients' enrolment in the study was in accordance with The European Association for the Study of the Liver (EASL) guidelines, 2016 and 2018[22,23]. All patients who were aged 18 years or over with a real-time RT-PCR diagnosis of chronic liver disease from HCV infection (*i.e.*, based on the presence of HCV RNA for over 6 mo) were included in the study.

Measurements

All the patients underwent full clinical assessment at baseline and after 12 wk of treatment. The baseline data collected included disease history and physical examination, complete blood count, prothrombin time, partial thromboplastin time (PTT), INR, serum total bilirubin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (gGT), albumin, creatinine, and serum HCV-RNA by real-time RT-PCR assay with lower limit of detection of 15 IU/mL (Abbott Real time HCV kits, m²000rt machine, Des Plaines, IL, 60018, United States). Abdominal ultrasound was carried out to detect the presence of liver cirrhosis and to exclude hepatocellular carcinoma and metastatic liver disease.

Treatment groups

The patients were classified into two groups, brand and generic. The brand group included 149 patients who were treated with brand antiviral therapy according to EASL guidelines, 2016 and 2018. The generic group included 140 patients treated with generic DAAs according to EASL guidelines, 2016 and 2018[22,23].

Most of the patients who were treated with brand antiviral agents received Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin [Omb/Par/Rit ± Das ± Rib; *n* = 44 (44.3%)], Sofosbuvir/Ledipasvir ± Ribavirin [Sof/Lep ± Rib; *n* = 55 (36.9%)], Sofosbuvir/Decatasvir ± Ribavirin [Sof/Dec ± Rib; *n* = 26 (17.4%)], and Sofosbuvir ± Ribavirin [Sof ± Rib; *n* = 2 (0.7%)]. These brand name agents included Sovaldi (Sofosbuvir), Harvoni (Sofosbuvir/Ledipasvir), Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir), Viekirax (Ombitasvir/Paritaprevir/Ritonavir), Daclinz (Daclatasvir), and Rebetol (Ribavirin), respectively. Of the patients treated with generic medications, 118 (84.3%) received Sofosbuvir/Daclatasvir ± Ribavirin [Sof/Dec ± Rib] while 22 (15.7%) received Sofosbuvir/Ledipasvir ± Ribavirin [Sof/Lep ± Rib]. These generic agents (all meant for use in Egypt) included Nucleobuvir (Sofosbuvir), Daclavirdine (Daclatasvir), Harvoni (Sofosbuvir/Ledipasvir), and Ribavirin (Ribavirin-Egypt). It should be noted that some of the generic medications used were produced by the same brand-name company at a lower price and for use only in LMICs such as Egypt.

Treatment outcomes

The primary study endpoint was the proportion of patients having HCV-RNA below detectable limits 12 wk post treatment (SVR) within each patient group, and comparing the findings of the patients who received brand *vs* generic DAAs. We also assessed the proportion of patients who abandoned treatment due to adverse effects of the antiviral therapy. Treatment failure was defined as the presence of HCV-RNA above detectable limits in patients after 12 wk of having completed therapy, irrespective of the type of DAAs received. Further clinical and laboratory evaluation was carried out at 12 wk post

treatment in order to compare the laboratory parameters at baseline and after treatment in each group.

Statistical analysis

Data analyses were performed using IBM SPSS Statistics for Windows (Version 24.0. Armonk, NY: IBM Corp, United States). The normality of continuous variables was assessed using the Shapiro-Wilk's test, and they are reported as the mean \pm standard deviation (SD), or for non-normally distributed variables as median (interquartile range). Categorical variables are presented as frequencies and percentages, and were compared using the Chi-Square test. Independent samples *t*-test was used to compare continuous variables with a normal distribution, while Mann-Whitney *U* test was used to compare non-normal continuous data. Paired *t*-test was used to compare continuous paired-samples of laboratory parameters before and at the end of treatment for each group. Univariate and multivariable logistic regression analyses were performed to determine the predictors of not achieving SVR 12 wk post treatment. Not achieving SVR was the dependent variable, while the treatment group was the main independent variable. Known predictors of SVR and variables with a *P* value of < 0.2 in the univariate analysis were the criteria for inclusion in the final model. A *P* value (two-sided) < 0.05 was considered statistically significant.

RESULTS

Characteristics of the patients

A total of 289 patients completed the study; 140 patients (48.4%) were treated with generic medications and 149 (51.6%) received brand medications. The demographic and clinical characteristics of the patients are shown in [Table 1](#). There were no significant sex differences in the study participants, and except for the serum level of PTT and platelet count, there were no significant differences in the laboratory parameters explored between patients who received generic and brand medications ([Table 1](#)). Patients who received brand medications had a higher proportion of co-morbidities, such as cirrhosis (33.6 *vs* 10.0%), diabetes mellitus (31.5 *vs* 10.7%), dyslipidemia (15.4 *vs* 5.7%), hypertension (24.8 *vs* 14.3%), and sickle cell disease (6 *vs* 5.7%), while those who received generic medication had a higher proportion of co-morbidities like hypothyroidism (5.0 *vs* 1.3%) and human immunodeficiency virus infection (2.1 *vs* 0.7%). The baseline median (interquartile range) HCV RNA level was 717465 (356749-1489 361) IU/mL in patients who received brand medications compared to 712023.5 (331131-1820183) IU/mL in those who received generic medications (Mann-Whitney *U* test; *P* = 0.81).

Treatment outcomes of the patients

By 12 wk following treatment, SVR was achieved by 271 (93.8%) of the patients. [Figure 1A-F](#) summarizes the outcomes of treatment among patients treated with brand and generic medications and their subgroups. Of the patients who were treated with generic medications, 134 (95.7%) achieved SVR at 12 wk post treatment. In comparison, 137 (91.9%) of the patients who were treated with brand DAAs achieved SVR at 12 wk post treatment ([Figure 1A](#); $\chi^2 = 1.76$, *P* = 0.19). In patients who received generic medications, 6 (4.3%) did not achieve SVR at 12 wk post treatment due to treatment failure, whereas for patients treated with brand medications, SVR was not achieved due to abandoning treatment for adverse effects in 7 (4.7%) patients, and to treatment failure in 5 (3.4%).

Among patients without liver cirrhosis ([Figure 1B](#)), 109 (96.5%) treated with generic medications and 88 (98.9%) treated with brand medications achieved SVR (*P* = 0.27). Similarly, among patients with cirrhosis ([Figure 1C](#)), there was no significant difference in the SVR rates between patients treated with brand and generic medications (*P* = 0.19). However, among patients with HCV genotype 1 ([Figure 1D](#)), 87 out of 88 patients (98.9%) treated with generic medications had SVR, compared to 100 of 109 (91.7%) patients who were treated with brand medications (*P* = 0.02). All patients with genotype 2, irrespective of the type of medication given, had SVR (100%). There was no significant difference in the SVR observed for patients with genotypes 3 and 4 according to the regimen received ([Figure 1E and F](#)).

Predictors of not achieving sustained virologic response

[Table 2](#) shows the predictors of not achieving SVR after 12 wk of treatment. In univariate analysis, having more than two co-morbidities and having ultrasound-diagnosed (USD) cirrhosis were significant determinants. On multivariable logistic regression analysis, being in the 40-65 years age group (odds ratio [OR]: 0.26, 95% confidence interval [CI]: 0.67-0.99), having USD cirrhosis (OR: 9.41, 95%CI: 2.47-35.84), and having HCV genotype 3 (OR: 3.56, 95%CI: 1.03-12.38) were significant independent predictors of not achieving SVR after 12 wk of treatment.

[Table 3](#) shows the predictors of not achieving SVR 12 wk post treatment in patients receiving only Sofosbuvir-based generic and brand medications. In univariate analysis, only having USD cirrhosis and having HCV genotype 3 were significant determinants. On multivariable logistic regression analysis, having USD cirrhosis (OR: 8.99, 95%CI: 1.83-44.16) and having HCV genotype 3 (OR: 4.44, 95%CI: 1.17-16.89) remained significant independent predictors of not achieving SVR 12 wk post treatment.

Table 1 Comparison of baseline data between the two groups, *n* = 289

Variable	Generic, <i>n</i> (%)	Brand, <i>n</i> (%)	<i>t</i> (χ^2) ^a statistic	<i>P</i>
Total	140	149		
Age (yr)			9.23 ^a	0.01
< 40	52 (37.1)	33 (22.1)		
40-65	73 (52.1)	103 (69.1)		
> 65	15 (10.7)	13 (8.7)		
Sex			0.23 ^a	0.63
Female	59 (42.1)	67 (45.0)		
Male	81 (57.9)	82 (55.0)		
Co-morbidities			32.28 ^a	< 0.001
None	65 (46.4)	25 (16.8)		
one to two	61 (43.6)	85 (57.0)		
More than two	14 (10.0)	39 (26.2)		
USD cirrhosis			15.10 ^a	< 0.001
No	113 (80.7)	89 (59.7)		
Yes	27 (19.3)	60 (40.3)		
HCV genotype			9.86 ^a	0.02
1	88 (62.9)	109 (73.2)		
2	4 (2.9)	2 (1.3)		
3	33 (23.6)	16 (10.7)		
4	15 (10.7)	22 (14.8)		
WBC ($\times 10^9$ /L) \pm SD	6.26 \pm 3.34	5.82 \pm 2.15	1.37	0.17
Haemoglobin (g/dL) \pm SD	12.50 \pm 2.52	12.80 \pm 2.12	-1.1	0.27
Platelets ($\times 10^9$ /L) \pm SD	232.35 \pm 108.08	189.01 \pm 95.48	3.62	< 0.001
PT (sec) \pm SD	14.11 \pm 11.94	13.3 \pm 1.88	0.8	0.43
PTT (sec) \pm SD	24.16 \pm 2.94	26.21 \pm 3.79	-5.1	< 0.001
INR \pm SD	1.08 \pm 0.18	1.31 \pm 2.22	-1.2	0.23
Creatinine (μ mol/L) \pm SD	66.86 \pm 21.07	89.68 \pm 148.85	-1.8	0.07
Albumin (g/L) \pm SD	41.04 \pm 5.11	38.81 \pm 6.05	3.36	0.01
Total bilirubin (μ mol/L) \pm SD	17.68 \pm 15.62	18.72 \pm 18.26	-0.52	0.6
ALP (U/L) \pm SD	93.31 \pm 43.54	102.02 \pm 43.79	-1.7	0.09
ALT (U/L) \pm SD	71.66 \pm 57.59	61.96 \pm 41.47	1.65	0.1
gGT(U/L) \pm SD	84.44 \pm 109.99	101.76 \pm 92.69	-1.45	0.15

^a*P* values based on Chi-square test or Student's *t*-test as appropriate.

Data are presented as proportion (%) or mean \pm SD or number. HCV: Hepatitis C virus; WBC: White blood cell count; USD: Ultrasound-diagnosed; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase.

Changes in laboratory parameters at baseline and after treatment

Table 4 shows the changes in the laboratory parameters at baseline and after treatment among patients treated with generic and brand medications. There was no significant difference in the WBC count before and after treatment among patients treated with generic medications (*P* = 0.15), but there was a significant increase in WBC among those treated with brand medications (*P* = 0.005). Treatment with both generic and brand medications were associated with a significant increase in serum albumin level (*P* < 0.001) and platelet count (*P* < 0.001). Similarly, treatment with both generic and brand medications

Table 2 Predictors of not achieving sustained virologic response in the overall sample identified using a multivariable regression model, *n* = 289

Variable	No SVR, <i>n</i> (%)	Crude OR, (95%CI)	Adjusted OR, (95%CI)	Adjusted <i>P</i>
Age (yr)				
< 40	6 (7.1)	1	1	
40-65	8 (4.5)	0.63 (0.21-1.87)	0.26 (0.67-0.99)	0.049
> 65	4 (14.3)	2.19 (0.57-8.42)	1.26 (0.23-6.96)	0.79
Sex				
Female	8 (4.8)	1	1	
Male	12 (7.4)	1.59 (0.58-4.36)	3.0 (0.87-10.37)	0.08
Co-morbidities				
None	2 (2.2)	1	1	
One to two	10 (6.8)	3.24 (0.69-15.12)	1.36 (0.22-8.38)	0.74
More than two	6 (11.3)	5.62 (1.09- 28.93)	3.63 (0.52-25.49)	0.19
USD cirrhosis				
No	5 (2.5)	1	1	
Yes	13 (14.9)	6.92 (2.39-20.10)	9.41 (2.47-35.84)	0.001
HCV genotype				
1	10 (4.9)	1	1	
3	6 (12.2)	2.69 (0.93-7.81)	3.56 (1.03-12.38)	0.044
4	2 (5.4)	1.10 (0.23-5.25)	0.69 (0.13-3.75)	0.67
DAC regimen				
Generic	6 (4.3)	1	1	
Brand	12 (8.1)	1.96 (0.71-5.36)	2.00 (0.57-7.04)	0.28
WBC ($\times 10^9$ /L)		1.04 (0.89-1.21)		
Haemoglobin (g/dL)		1.14 (0.92-1.41)		
Platelets ($\times 10^9$ /L)		1.00 (0.96-1.01)		
PT (sec)		1.02 (0.95-1.05)		
PTT (sec)		1.12 (0.98-1.29)		
INR		0.99 (0.72-1.38)		
Creatinine (μ mol/L)		1.00 (0.98-1.01)		
Albumin (g/L)		0.98 (0.90-1.06)		
Total bilirubin (μ mol/L)		0.99 (0.96-1.03)		
ALP (U/L)		1.05 (0.99-1.02)		
ALT (U/L)		1.01 (1.00-1.02)		
gGT(U/L)		1.03 (1.00-1.06)		

HCV: Hepatitis C virus; WBC: White blood cell count; USD: Ultrasound-diagnosed; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase; SVR: Sustained virologic response; 95%CI: 95% confidence interval; OR: Odds ratio.

were associated with a significant decline in serum total bilirubin ($P < 0.05$), serum ALT ($P < 0.001$), and gGT ($P < 0.001$). Generic medication use was associated with a significant reduction in serum ALP levels at the end of treatment ($P < 0.001$); however, treatment with brand medications was associated with an insignificant reduction in serum ALP levels (Table 4).

Table 3 Predictors of not achieving sustained virologic response in patients receiving only sofosbuvir-based therapy identified using a multivariable regression model, *n* = 223

Variable	No SVR, <i>n</i> (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	Adjusted <i>P</i>
Age (yr)				
< 40	5 (7.5)	1	1	
40-65	6 (4.5)	0.58 (0.17-1.98)	0.30 (0.07-1.35)	0.12
> 65	20 (9.1)	1.24 (0.22-6.89)	0.69 (0.08-5.81)	0.73
Sex				
Female	4 (4.3)	1	1	
Male	9 (6.9)	1.66 (0.49-5.55)	2.33 (0.57-9.53)	0.24
Co-morbidities				
None	2 (2.6)	1	1	
One to two	7 (6.3)	2.47 (0.50-12.21)	1.03 (0.14-7.61)	0.98
More than two	4 (11.4)	4.77 (0.83-27.43)	3.45 (0.41-29.05)	0.26
USD cirrhosis				
No	4 (2.6)	1	1	
Yes	9 (13.2)	5.76 (1.71-19.42)	8.99 (1.83-44.16)	0.007
HCV genotype				
1	6 (4.1)	1	1	
3	6 (12.2)	3.30 (1.01-10.77)	4.44 (1.17-16.89)	0.03
4	1 (3.8)	0.95 (0.11-8.20)	0.95 (0.10-9.45)	0.96
DAC regimen				
Generic	6 (4.3)	1	1	
Brand	7 (8.4)	2.06 (0.67-6.34)	1.42 (0.34-5.94)	0.63
WBC ($\times 10^9$ /L)		0.98 (0.80-1.21)		
Haemoglobin (g/dL)		1.15 (0.89-1.48)		
Platelets ($\times 10^9$ /L)		1.00 (0.99-1.01)		
PT (sec)		1.02 (0.95-1.06)		
PTT (sec)		1.17 (1.00-1.37)		
INR		1.00 (0.72-1.38)		
Creatinine (μ mol/L)		1.00 (0.97-1.03)		
Albumin (g/L)		0.97 (0.90-1.06)		
Total bilirubin (μ mol/L)		0.99 (0.95-1.03)		
ALP (U/L)		1.01 (1.00-1.02)		
ALT (U/L)		1.01 (1.00-1.02)		
gGT(U/L)		1.03 (1.00-1.07)		

HCV: Hepatitis C virus; WBC: White blood cell count; USD: Ultrasound-diagnosed; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase; SVR: Sustained virologic response; 95%CI: 95% confidence interval; OR: Odds ratio.

DISCUSSION

The adoption of a new low-cost generic DAA therapy for the treatment of chronic HCV infection has remained a game changer for several national treatment programs as it has improved access to treatment and has provided significant progress towards the elimination of HCV. In most countries, generic formulations are required to undergo pharmaco-equivalence studies[9,12] and are therefore

Table 4 Changes in laboratory parameters before or at the end of treatment (12 wk) among patients who received generic and brand direct antiviral agents

Variable	Period	Generic, mean \pm SD	P	Brand, mean \pm SD	P
WBC ($\times 10^9$ /L)	wk 0	6.27 \pm 3.34	0.15	5.82 \pm 2.15	0.005
	EOT	6.67 \pm 3.62		6.13 \pm 2.40	
Haemoglobin (g/dL)	wk 0	12.50 \pm 2.52	0.17	12.81 \pm 2.12	0.94
	EOT	12.71 \pm 2.44		12.81 \pm 2.25	
Platelets ($\times 10^9$ /L)	wk 0	232.35 \pm 108.1	< 0.001	189.01 \pm 95.48	< 0.001
	EOT	257.63 \pm 113.11		210.85 \pm 100.69	
PT (sec)	wk 0	14.11 \pm 11.93	0.52	13.32 \pm 1.88	0.91
	EOT	13.31 \pm 8.79		13.30 \pm 1.91	
PTT (sec)	wk 0	24.16 \pm 2.91	0.001	26.20 \pm 3.79	0.22
	EOT	23.14 \pm 4.25		25.90 \pm 3.22	
INR	wk 0	1.08 \pm 0.18	0.7	1.31 \pm 2.22	0.31
	EOT	1.11 \pm 0.87		1.12 \pm 0.17	
Creatinine (μ mol/L)	wk 0	66.86 \pm 21.07	0.05	89.68 \pm 148.85	0.55
	EOT	70.50 \pm 31.94		92.05 \pm 138.93	
Albumin (g/L)	wk 0	41.04 \pm 5.11	< 0.001	38.82 \pm 6.05	< 0.001
	EOT	42.78 \pm 5.46		40.90 \pm 5.48	
Total bilirubin (μ mol/L)	wk 0	17.68 \pm 15.62	< 0.001	18.72 \pm 18.26	0.004
	EOT	14.30 \pm 12.64		15.14 \pm 13.74	
ALP (U/L)	wk 0	93.31 \pm 43.55	< 0.001	102.02 \pm 43.79	0.18
	EOT	77.32 \pm 32.65		94.79 \pm 73.56	
ALT (U/L)	wk 0	71.66 \pm 57.59	< 0.001	61.96 \pm 41.47	< 0.001
	EOT	27.09 \pm 33.56		29.09 \pm 24.58	
gGT(U/L)	w 0	84.44 \pm 109.98	< 0.001	101.76 \pm 92.69	< 0.001
	EOT	43.48 \pm 62.65		50.64 \pm 53.37	

P values are based on paired *t*-tests. EOT: End of treatment; WBC: White blood cell count; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase.

required to demonstrate a similar rate of absorption and bioavailability compared to the original brand drug before its approval for use. Several studies carried out in multiple countries have shown that generic and brand DAAs have similar bioequivalence[13,24]. Several studies have revealed the real-life effectiveness of generic DAAs[7,14,15], but only a few studies have assessed their clinical efficacy compared to the original brand DAAs. This study is a comparative assessment of chronic hepatitis C patients treated with either brand or generic DAAs. Although we did not randomize the study patients, most of the baseline laboratory tests and viral load did not significantly differ between patients treated with generic or brand DAAs. However, the patients significantly differed in their age group, HCV genotype, and number of co-morbidities including the proportion with USD cirrhosis.

In this study, we compared the safety and efficacy of generic *vs* brand DAAs for the treatment of chronic hepatitis C. The study findings revealed that the generic DAAs used were very effective with an SVR rate of 95.7% compared with 91.9% in patients receiving brand DAAs. Our findings are generally consistent with the findings of other studies. In Argentina, Marciano *et al*[25] compared treatment with generic or brand Sofosbuvir-based therapy for 321 patients with chronic hepatitis C, of whom 91% had cirrhosis. The study revealed an SVR rate of 91% among patients receiving brand and 89% among those receiving generic Sofosbuvir-based regimen. In Egypt, two studies among patients with chronic hepatitis C revealed SVR rates of 98.2%-100% among patients receiving generic DAAs compared with rates of 98.1%-99% in those receiving brand DAAs[17,18]. In India, Tang *et al*[16] carried out a non-randomized comparative study among 66 patients with chronic hepatitis C. SVR rates were 72.4% *vs* 75.7% among patients treated with generic *vs* brand DAAs. The lower SVR rates in the studies from




Figure 1 Virologic response among patients. A: Percentage among all patients; B: Percentage among patients without cirrhosis; C: Percentage among patients with cirrhosis; D: Percentage among patients with HCV genotype 1; E: Percentage among patients with HCV genotype 3; F: Percentage among patients with HCV genotype 4.

Argentina and India compared to ours may be due to a higher proportion of patients with cirrhosis, and some of their patients were previously treated cases who had treatment failure[16,25]. Overall, our study adds to the literature on the similarity in effectiveness in patients receiving both brand and generic formulations of DAAs for chronic hepatitis C.

Being a middle-aged patient, having USD cirrhosis, and having genotype 3 were all predictors of not achieving SVR. Middle-aged patients were 74% less likely to achieve SVR while patients with cirrhosis were 9.4 times less likely to achieve SVR, and patients with HCV genotype 3 were almost 4 times less likely to do so. Furthermore, our analysis revealed that receiving brand or generic DAAs was not an independent risk factor for not achieving SVR. Moreover, when we restricted our analysis to patients treated with Sofosbuvir-based brand and generic regimens, our study revealed that having cirrhosis and genotype 3 were the independent predictors of not achieving SVR. A previous study in the same setting using brand DAAs for hepatitis C treatment revealed that having cirrhosis at baseline was the only risk factor for not achieving SVR [21]. The findings of this study indicate that adequate care and attention need to be given during treatment of patients with cirrhosis and genotype 3 HCV in our setting. Another study found that having positive HCV RNA at 4 wk post treatment was a risk factor for not achieving SVR[17]. In the present study, we did not assess the level of HCV RNA at 4 wk post treatment. This should be considered in future studies.

In terms of safety, this study revealed that 4.3% of HCV infected patients treated with generic DAAs had treatment failure compared with 3.4% among patients who received brand DAAs. None of the patients who received generic DAAs abandoned treatment due to adverse drug reaction/effects while 4.7% of those receiving brand DAAs did. Considering intention-to-treat analysis, although the proportion of patients with a poor outcome was higher among patients treated with brand medications, the difference was not statistically significant. Similar findings were documented by other investigators and this suggests that the safety profile of both generic and brand DAAs for HCV infection treatment are good. Both the generic and brand DAA formulations resulted in significant changes in the level of serum transaminases and hemoglobin level, and this is consistent with findings of previous studies involving brand or generic DAAs[26-30]. Total bilirubin substantially decreased at 12 wk post treatment [17,26,27,30,30]. ALP, ALT, and gGT all substantially declined at 12 wk post treatment when compared to baseline values in both groups in accordance with previously published reports.

This study has some limitations. This was a non-randomized retrospective observational clinical study from a single center. Not all the patients received the same type of brand or generic DAA

formulation, which might have accounted for minor differences in the treatment outcome. The type of DAA medication given to the patients was based on the EASL guidelines at the time of enrolment[22, 23]. Another important limitation is that, although the majority of our patients were treatment naïve, we do not have data on the proportion of previously treated hepatitis C patients included in this analysis, which might have affected the treatment outcomes[16-18]. This should be considered during further studies in our setting. Moreover, other factors that might have influenced the treatment outcome is the choice of the DAA medication used. In our study, the choice of DAA regimen used was physician driven, *i.e.*, based on the physicians' interest in treating the greatest number of patients effectively considering the best available evidence, as well as the most effective medications according to the patients' profile at a reduced cost.

CONCLUSION

This study shows that generic and brand DAAs demonstrated comparable effectiveness in the treatment of chronic hepatitis C patients, were well tolerated, and were equally effective in improving biochemical markers of hepatic inflammation. Therefore, generic DAAs could revolutionize the treatment of hepatitis C – providing access to treatment for millions of people infected with HCV. Closer monitoring should be given to HCV infected patients with HCV genotype 3 and cirrhosis during treatment.

ARTICLE HIGHLIGHTS

Research background

Direct acting antiviral (DAA) agents have revolutionized the treatment of hepatitis C virus (HCV) infection because they are highly effective. However, brand DAA agents are very expensive and unaffordable to many patients who need them. Generic versions of the DAA agents are being developed to address this challenge but research on whether their effectiveness is comparable to brand DAA agents are limited.

Research motivation

Data on the clinical efficacy of generic DAA agents for chronic HCV infection treatment is rare in Bahrain.

Research objectives

This study evaluated the effectiveness and safety of generic compared to brand DAA agents for chronic HCV infection treatment.

Research methods

In this observational study, 149 patients were enrolled and treated with brand DAA agents (brand group), and another 140 patients were enrolled and treated with generic versions of DAA agents (generic group) over a two-year period. The primary outcomes included sustained virologic response after 12 wk of treatment and its determinants.

Research results

In general, there was no significant differences in the treatment outcome of patients who received brand *vs* generic DAA agents in terms of their sustained virologic response after 12 wk of treatment. Both generic and brand DAAs showed marked improvement in liver function evidenced by a substantial reduction in serum alanine and aspartate aminotransferase levels and total bilirubin levels. Overall, patients who had cirrhosis and HCV genotype 3 were significantly less likely to achieve sustained virologic response after 12 wk of treatment.

Research conclusions

Generic DAA agents have similar clinical efficacy and safety levels compared to brand DAA agents in the treatment of chronic HCV infection. They also show similarity in their improvement of hepatic function in these patients.

Research perspectives

Further studies are needed to better evaluate the long-term efficacy and safety of generic direct acting antiviral (DAA) agents in previously treated hepatitis C virus (HCV) infected patients and in patients with cirrhosis and HCV genotype 3.

FOOTNOTES

Author contributions: Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, and Al Qamish J contributed equally to this work; Abdulla M and Al Qamish J designed the research study; Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, and Al Qamish J performed the research; Husain HAHY, Al Ghareeb AM, and Mohammed N contributed new reagents and analytic tools; Abdulla M, Husain HAHY, and Mohammed N analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.

Institutional review board statement: The study was approved by the Secondary Health Care Research Sub Committee, Ministry of Health, Kingdom of Bahrain (Reference number 22G45-40-01925).

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at amaheeba@gmail.com.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Bahrain

ORCID number: Maheeba Abdulla 0000-0001-5319-2892; Aysha Mohamed Al Ghareeb 0000-0000-0000; Hamed Ali Hasan Yusuf Husain 0000-0000-0000; Nafeesa Mohammed 0000-0003-4718-9325; Jihad AlQamish 0000-0001-8597-9913.

S-Editor: Ma YJ

L-Editor: Wang TQ

P-Editor: Ma YJ

REFERENCES

- 1 **World Health Organization.** Global hepatitis report 2017. World Health Organization; Geneva 2017. Available from: <https://www.who.int/publications/i/item/9789241565455>
- 2 **GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.** Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789-1858 [PMID: 30496104 DOI: 10.1016/S0140-6736(18)32279-7]
- 3 **World Health Organization.** Hepatitis C fact sheet. Available from: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c> (accessed 20/02/2022)
- 4 **Nahon P,** Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS CO12 CirVir Group. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. *Gastroenterology* 2017; **152**: 142-156.e2 [PMID: 27641509 DOI: 10.1053/j.gastro.2016.09.009]
- 5 **Ferrarese A,** Germani G, Gambato M, Russo FP, Senzolo M, Zanetto A, Shalaby S, Cillo U, Zanusi G, Angeli P, Burra P. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. *World J Gastroenterol* 2018; **24**: 4403-4411 [PMID: 30344424 DOI: 10.3748/wjg.v24.i38.4403]
- 6 **Morgan RL,** Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med* 2013; **158**: 329-337 [PMID: 23460056 DOI: 10.7326/0003-4819-158-5-201303050-00005]
- 7 **Perazzo H,** Castro R, Luz PM, Banholi M, Goldenzon RV, Cardoso SW, Grinsztejn B, Veloso VG. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. *Bull World Health Organ* 2020; **98**: 188-197K [PMID: 32132753 DOI: 10.2471/BLT.19.231522]
- 8 **Falade-Nwulia O,** Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. *Ann Intern Med* 2017; **166**: 637-648 [PMID: 28319996 DOI: 10.7326/M16-2575]
- 9 **World Health Organization.** Guidelines for the Care and Treatment of Persons Diagnosed With Chronic Hepatitis C Virus Infection 2018. Available from: www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en (accessed 20/02/2022)

- 10 **Iyengar S**, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS Med* 2016; **13**: e1002032 [PMID: [27243629](#) DOI: [10.1371/journal.pmed.1002032](#)]
- 11 **Baumert TF**, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. *Gastroenterology* 2019; **156**: 431-445 [PMID: [30342035](#) DOI: [10.1053/j.gastro.2018.10.024](#)]
- 12 **World Health Organization**. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low and middle income countries 2018; Geneva, Switzerland. Available from: <https://apps.who.int/iris/handle/10665/260445>
- 13 **Hill A**, Tahat L, Mohammed MK, Tayyem RF, Khwairakpam G, Nath S, Freeman J, Benbitour I, Helmy S. Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals. *J Virus Erad* 2018; **4**: 128-131 [PMID: [29682307](#)]
- 14 **Gupta S**, Rout G, Patel AH, Mahanta M, Kalra N, Sahu P, Sethia R, Agarwal A, Ranjan G, Kedia S, Acharya SK, Nayak B, Shalimar. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection. *J Viral Hepat* 2018; **25**: 771-778 [PMID: [29377464](#) DOI: [10.1111/jvh.12870](#)]
- 15 **Zeng QL**, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, Liang HX, Li CX, Yu ZJ. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. *J Hepatol* 2017; **66**: 1123-1129 [PMID: [28189754](#) DOI: [10.1016/j.jhep.2017.01.025](#)]
- 16 **Tang L**, Kamat M, Shukla A, Vora M, Kalal C, Kotttilil S, Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. *Interdiscip Perspect Infect Dis* 2018; **2018**: 9124604 [PMID: [30364048](#) DOI: [10.1155/2018/9124604](#)]
- 17 **Abozeid M**, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, Elfayomy M, Abdel-Ghaffar TS, Abdelkareem M, Sabry A, Fekry M, Shebl N, Rewisha E, Waked I. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. *Int J Infect Dis* 2018; **75**: 109-114 [PMID: [30077791](#) DOI: [10.1016/j.ijid.2018.07.025](#)]
- 18 **El-Nahaas SM**, Fouad R, Elsharkawy A, Khairy M, Elhossary W, Anwar I, Abdellatif Z, Maher RM, Bekheet N, Esmat G. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. *Eur J Gastroenterol Hepatol* 2018; **30**: 1194-1199 [PMID: [30096091](#) DOI: [10.1097/MEG.0000000000001228](#)]
- 19 **Abdulla MA**, Murad EA, Aljenaidi HA, Aljowder DR, Aljeeran OI, Farid E, Al Qamish JR. Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain. *Hepat Med* 2017; **9**: 7-11 [PMID: [28280398](#) DOI: [10.2147/HMER.S124274](#)]
- 20 **Janahi EM**, Al-Mannai M, Singh H, Jahromi MM. Distribution of Hepatitis C Virus Genotypes in Bahrain. *Hepat Mon*. 2015;15(12):e30300. DOI: [10.5812/hepatmon.30300](#)
- 21 **Abdulla M**, Ali H, Nass H, Khamis J, AlQamish J. Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain. *Hepat Med* 2019; **11**: 69-78 [PMID: [31191049](#) DOI: [10.2147/HMER.S190967](#)]
- 22 **European Association for the Study of the Liver**. EASL Recommendations on Treatment of Hepatitis C 2016. *J Hepatol* 2017; **66**: 153-194 [PMID: [27667367](#) DOI: [10.1016/j.jhep.2016.09.001](#)]
- 23 **European Association for the Study of the Liver**. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol* 2018; **69**: 461-511 [PMID: [29650333](#) DOI: [10.1016/j.jhep.2018.03.026](#)]
- 24 **Bendas ER**, Rezk MR, Badr KA. Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers. *Clin Drug Investig* 2018; **38**: 439-448 [PMID: [29417463](#) DOI: [10.1007/s40261-018-0622-8](#)]
- 25 **Marciano S**, Haddad L, Reggiardo MV, Peralta M, Vistarini C, Marino M, Descalzi VI, D'Amico C, Figueroa Escuti S, Gaité LA, Perez Ravier R, Longo C, Borzi SM, Galdame OA, Bessone F, Fainboim HA, Frías S, Cartier M, Gadano AC. Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study. *J Med Virol* 2018; **90**: 951-958 [PMID: [29350402](#) DOI: [10.1002/jmv.25033](#)]
- 26 **Deterding K**, Höner Zu Siederdisen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D, Mix H, Manns MP, Cornberg M, Wedemeyer H. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. *Aliment Pharmacol Ther* 2015; **42**: 889-901 [PMID: [26250762](#) DOI: [10.1111/apt.13343](#)]
- 27 **Raschzok N**, Schott E, Reutzel-Selke A, Damrah I, Gül-Klein S, Strücker B, Sauer IM, Pratschke J, Eurich D, Stockmann M. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C. *Transpl Infect Dis* 2016; **18**: 896-903 [PMID: [27632190](#) DOI: [10.1111/tid.12606](#)]
- 28 **Elsharkawy A**, Eletreby R, Fouad R, Soliman Z, Abdallah M, Negm M, Mohey M, Esmat G. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. *Expert Rev Gastroenterol Hepatol* 2017; **11**: 773-778 [PMID: [28480808](#) DOI: [10.1080/17474124.2017.1326816](#)]
- 29 **Mohamed MS**, Hanafy AS, Bassiony MAA, Hussein S. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. *Eur J Gastroenterol Hepatol* 2017; **29**: 1368-1372 [PMID: [28953002](#) DOI: [10.1097/MEG.0000000000000963](#)]
- 30 **Lourenço MS**, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. *World J Hepatol* 2022; **14**: 195-208 [PMID: [35126848](#) DOI: [10.4254/wjh.v14.i1.195](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

